{
    "2019-08-29": [
        [
            {
                "time": "2018-03-15",
                "original_text": "U.S. FDA approves Mylan generic of Lilly lung cancer drug Alimta",
                "features": {
                    "keywords": [
                        "FDA",
                        "approves",
                        "Mylan",
                        "generic",
                        "Lilly",
                        "lung cancer",
                        "Alimta"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-16",
                "original_text": "Mylan Stock Leaps As It Prepares To Knock Off $2 Billion Lilly Drug",
                "features": {
                    "keywords": [
                        "Mylan",
                        "Stock",
                        "Leaps",
                        "Knock Off",
                        "Lilly",
                        "Drug"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-17",
                "original_text": "Lilly (LLY) Up 1.9% Since Last Earnings Report: Can It Continue?",
                "features": {
                    "keywords": [
                        "Lilly",
                        "LLY",
                        "Up",
                        "Earnings",
                        "Report"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}